Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency

PURPOSE: Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/M...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Anirban, Tabori, Uri, Sambira Nahum, Lauren C., Collins, Natalie B., Deyell, Rebecca, Dvir, Rina, Faure-Conter, Cecile, Hassall, Timothy E., Minturn, Jane E., Edwards, Melissa, Brookes, Elissa, Bianchi, Vanessa, Levine, Adrian, Stone, Simone C., Sudhaman, Sumedha, Sanchez Ramirez, Santiago, Ercan, Ayse B., Stengs, Lucie, Chung, Jill, Negm, Logine, Getz, Gad, Maruvka, Yosef E., Ertl-Wagner, Birgit, Ohashi, Pamela S., Pugh, Trevor, Hawkins, Cynthia, Bouffet, Eric, Morgenstern, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690097/
https://www.ncbi.nlm.nih.gov/pubmed/37126021
http://dx.doi.org/10.1158/1078-0432.CCR-23-0411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690097/
https://www.ncbi.nlm.nih.gov/pubmed/37126021
http://dx.doi.org/10.1158/1078-0432.CCR-23-0411

Ejemplares similares